Biogen Inc. (NASDAQ: BIIB) stock is seeing muted sentiment Tuesday as it emerges from the euphoria over Aduhelm approval, with the most recent trigger being lukewarm data for a partnered program. The …
More Biogen Analyst Raises Price Target On Higher Chance Of Success For Depression Drug Videos